Industry Insights Integrating Organotypic 3D Microtissue Models with Analytics to Advance Predictive Drug Development

Related Vendors

Sartorius AG

DÜPERTHAL Sicherheitstechnik GmbH & Co. KG

TURCK GmbH

EDL Anlagenbau Gesellschaft mbH

Despite substantial investment in pharmaceutical R&D, clinical success rates remain low. As it stands, 90 % of drug candidates entering human trials fail due to unforeseen toxicity or limited efficacy in humans. A key contributor to this attrition is the limited predictive power of traditional preclinical models, particularly 2D cell cultures and animal studies, which often fall short in recapitulating the complexity of human biology. This gap is particularly evident in oncology and organ-specific toxicity assessments, where cellular context and microenvironmental interactions play a critical role in drug response.

To bridge this translational divide, researchers are turning to organotypic 3D microtissue models that more faithfully replicate in vivo physiology. When combined with high content imaging and quantitative analysis tools, these models offer a scalable, reproducible, and human-relevant platform for evaluating therapeutic efficacy and safety.

Achieving predictive power requires data-rich, kinetic analytics. High-throughput live-cell analysis enables continuous, non-perturbing imaging of tissue viability and morphology for both discovery and safety pipelines: